Yale Podnos sold $150k of STLN
Chief Medical Officer at Oncology Institute, Inc.. 23,452 shares at an average of $6.41, traded Jul 14, 2026, filed Jul 16, 2026.
Score components
- +15RoleOfficer
- +11Trade size$150k at market
- 0Share of holdings soldSold 8.5% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001553350-26-000111, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | MOption exercise Common Stock10b5-1 | +17,974 | $1.87 | $34k | 277,501 | Jul 16, 2026 |
| Jul 14, 2026 | SOpen-market sale Common Stock10b5-1 | -17,974 | $6.43 | $116k | 259,527 | Jul 16, 2026 |
| Jul 14, 2026 | MOption exercise Common Stock10b5-1 | +5,478 | $2.00 | $11k | 265,005 | Jul 16, 2026 |
| Jul 14, 2026 | SOpen-market sale Common Stock10b5-1 | -5,478 | $6.35 | $35k | 259,527 | Jul 16, 2026 |
| Jul 14, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +17,974 | $1.87 | $34k | 0 | Jul 16, 2026 |
| Jul 14, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | +5,478 | $2.00 | $11k | 0 | Jul 16, 2026 |
Related signals
Other insiders at Oncology Institute, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Oncology Institute, Inc. | Brad Hively director | $1.9M 298,853 shares | -42% | |
| 26Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $78k 12,000 shares | +0% | |
| 27Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $95k 18,000 shares | +0% | |
| 26Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $88k 15,000 shares | +0% | |
| 16Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $90k 18,000 shares | +0% | |
| 6Weak | Oncology Institute, Inc. | Yale Podnos Chief Medical Officer | $126k 23,451 shares | -8% | |
| 14Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $57k 12,000 shares | +0% | |
| 18Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $157k 38,500 shares | +0% | |
| 17Weak | STLNbuy Oncology Institute, Inc. | Jorey Chernett owner | $123k 30,000 shares | +0% | |
| 20Weak | Oncology Institute, Inc. | Mohit Kaushal director | $335k 95,719 shares | -36% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.